BrightInsight Announces Enterprise Agreement with CSL Behring
BrightInsight Inks Enterprise Agreement with CSL Behring for Digital Health Solutions Across Brand Portfolio
November 14, 2022 08:30 ET | BrightInsight
SAN JOSE, Calif. and LAS VEGAS, Nov. 14, 2022 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, today at...
Axtria Leads Discuss
Axtria Leads Discussion on Pharma’s Advanced Uses of Data Analytics and Artificial Intelligence With 6 Sessions at PMSA 2021 Annual Conference
June 16, 2021 08:00 ET | Axtria Inc.
Berkeley Heights, NJ, June 16, 2021 (GLOBE NEWSWIRE) -- With the elevated importance of data analytics and artificial intelligence (AI)-driven intelligence technology systems for a global life...
uniQure announces closing of commercialization and license agreement with CSL Behring
May 06, 2021 07:00 ET | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, May 06, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure Announces License Agreement with CSL Behring to Commercialize Hemophilia B Gene Therapy
June 24, 2020 16:05 ET | uniQure Inc.
~ CSL Behring Obtains Exclusive Global Rights to Develop and Commercialize uniQure’s Differentiated Gene Therapy Candidate for Hemophilia B ~ ~ uniQure Eligible to Receive More Than $2 Billion,...
BirghtInsight Logo 3 24 20.png
BrightInsight and CSL Behring Announce Global Digital Health Partnership to Improve Treatment Experience for Patients with Rare Diseases
May 06, 2020 08:30 ET | BrightInsight; CSL Behring
SAN JOSE, Calif. and KING OF PRUSSIA, Pa., May 06, 2020 (GLOBE NEWSWIRE) -- BrightInsight, Inc., the provider of the leading regulated IoT platform for biopharma and medtech, and CSL Behring, a...